Selecta Biosciences (SELB) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS
Selecta Biosciences (NASDAQ:SELB) issued its quarterly earnings results on Thursday. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.08, MarketWatch Earnings reports.
SELB stock traded down $0.29 during mid-day trading on Friday, reaching $5.51. The company had a trading volume of 347,760 shares, compared to its average volume of 444,699. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. The company has a market capitalization of $129.90 million, a P/E ratio of -1.72 and a beta of 0.91. Selecta Biosciences has a 12 month low of $4.74 and a 12 month high of $16.55.
Several brokerages recently commented on SELB. UBS Group set a $6.00 price target on shares of Selecta Biosciences and gave the company a “hold” rating in a report on Friday. BidaskClub downgraded shares of Selecta Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Mizuho restated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research note on Monday, November 5th. Zacks Investment Research upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, Stifel Nicolaus initiated coverage on shares of Selecta Biosciences in a research note on Friday, September 14th. They issued a “buy” rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Selecta Biosciences presently has a consensus rating of “Hold” and an average price target of $23.83.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.